Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-908-4431860
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees15
Next Earnings Date4/7/2020 (Estimated)
OptionableNot Optionable
Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions
What is Matinas BioPharma's stock symbol?
Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."
How were Matinas BioPharma's earnings last quarter?
Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) issued its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.03) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.03). View Matinas BioPharma's Earnings History.
When is Matinas BioPharma's next earnings date?
What price target have analysts set for MTNB?
4 equities research analysts have issued 12-month price targets for Matinas BioPharma's shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate Matinas BioPharma's share price to reach $4.19 in the next year. This suggests a possible upside of 365.3% from the stock's current price. View Analyst Price Targets for Matinas BioPharma.
What is the consensus analysts' recommendation for Matinas BioPharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Matinas BioPharma.
What are Wall Street analysts saying about Matinas BioPharma stock?
Here are some recent quotes from research analysts about Matinas BioPharma stock:
- 1. HC Wainwright analysts commented, "Our price target of $4/share is based on an equally weighted composite of: (a) $2.47/share, as a 35x multiple of taxed and diluted 2033 EPS of $0.67 discounted back to 2019 at 18%; and (b) an NPV discounted cash flow between 2019-2033 of $4.81/share, with a discount rate of 12% and growth rate of 2%. These assumptions are in-line with the expected PE multiple and discount rates of an early development-stage biopharmaceutical company." (8/14/2019)
- 2. According to Zacks Investment Research, "Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia. " (7/17/2019)
- 3. Maxim Group analysts commented, "Matinas reported 1Q19 with a net loss of ($4.3M) and cash of $39.4M. This included a $32.4M financing completed in March, which should provide funding into 2021." (5/16/2019)
Has Matinas BioPharma been receiving favorable news coverage?
News articles about MTNB stock have been trending somewhat negative this week, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Matinas BioPharma earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Matinas BioPharma.
Are investors shorting Matinas BioPharma?
Matinas BioPharma saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 5,530,000 shares, an increase of 5.1% from the September 30th total of 5,260,000 shares. Based on an average daily trading volume, of 520,300 shares, the days-to-cover ratio is currently 10.6 days. Approximately 4.0% of the company's stock are sold short. View Matinas BioPharma's Current Options Chain.
Who are some of Matinas BioPharma's key competitors?
Some companies that are related to Matinas BioPharma include Starpharma (SPL), TELIX Pharmaceutical (TLX), Biotest (BIO), BELLUS Health (BLU), Oxford BioMedica (OXB), Bellus Health (BLU), Theratechnologies (TH), Neptune Wellness Solutions (NEPT), Resverlogix (RVX), ProMetic Life Sciences (PLI), Rafael (RFL), Silence Therapeutics (SLN), Pfenex (PFNX), CEL-SCI (CVM) and Neuren Pharmaceuticals (NEU).
What other stocks do shareholders of Matinas BioPharma own?
Who are Matinas BioPharma's key executives?
Matinas BioPharma's management team includes the folowing people:
- Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 45)
- Dr. Raphael J. Mannino, Sr. VP & Chief Scientific Officer (Age 72)
- Mr. Keith A. Kucinski CPA, M.B.A., Chief Financial Officer (Age 49)
- Dr. Theresa Matkovits, Chief Devel. Officer (Age 52)
- Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply Chain
How do I buy shares of Matinas BioPharma?
Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Matinas BioPharma's stock price today?
One share of MTNB stock can currently be purchased for approximately $0.90.
How big of a company is Matinas BioPharma?
What is Matinas BioPharma's official website?
How can I contact Matinas BioPharma?
Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.
MarketBeat Community Rating for Matinas BioPharma (NYSEAMERICAN MTNB)
MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote "Outperform" if you believe MTNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTNB will underperform the S&P 500 over the long term. You may vote once every thirty days.
